Cencora Valuation
Is 0HF3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0HF3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0HF3 ($251.06) is trading below our estimate of fair value ($676.97)
Significantly Below Fair Value: 0HF3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0HF3?
Key metric: As 0HF3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0HF3's PE Ratio? | |
|---|---|
| PE Ratio | 32x |
| Earnings | US$1.51b |
| Market Cap | US$48.26b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | 12.3x |
| PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does 0HF3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28x | ||
SN. Smith & Nephew | 35.7x | 22.5% | UK£8.7b |
MDC Mediclinic International | 21.9x | 10.7% | UK£3.7b |
CAH Cardinal Health | 23.2x | 7.7% | US$29.6b |
MCK McKesson | 31.4x | 15.0% | US$79.3b |
0HF3 Cencora | 32x | 14.6% | US$48.3b |
Price-To-Earnings vs Peers: 0HF3 is expensive based on its Price-To-Earnings Ratio (32x) compared to the peer average (30.2x).
Price to Earnings Ratio vs Industry
How does 0HF3's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0HF3 is expensive based on its Price-To-Earnings Ratio (32x) compared to the European Healthcare industry average (18.8x).
Price to Earnings Ratio vs Fair Ratio
What is 0HF3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32x |
| Fair PE Ratio | 41.4x |
Price-To-Earnings vs Fair Ratio: 0HF3 is good value based on its Price-To-Earnings Ratio (32x) compared to the estimated Fair Price-To-Earnings Ratio (41.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$251.06 | US$267.32 +6.5% | 7.9% | US$292.00 | US$230.00 | n/a | 16 |
| Nov ’25 | US$234.88 | US$257.32 +9.6% | 7.6% | US$287.00 | US$215.00 | n/a | 16 |
| Oct ’25 | US$224.19 | US$259.92 +15.9% | 7.5% | US$287.00 | US$215.00 | n/a | 16 |
| Sep ’25 | US$237.74 | US$262.05 +10.2% | 7.5% | US$287.00 | US$215.00 | n/a | 16 |
| Aug ’25 | US$242.09 | US$260.98 +7.8% | 7.7% | US$287.00 | US$215.00 | n/a | 16 |
| Jul ’25 | US$223.52 | US$255.98 +14.5% | 9.0% | US$280.00 | US$194.00 | n/a | 16 |
| Jun ’25 | US$223.87 | US$255.33 +14.1% | 9.3% | US$280.00 | US$194.00 | n/a | 15 |
| May ’25 | US$231.02 | US$254.84 +10.3% | 8.6% | US$280.00 | US$194.00 | n/a | 16 |
| Apr ’25 | US$241.08 | US$247.84 +2.8% | 10.4% | US$270.00 | US$183.00 | n/a | 16 |
| Mar ’25 | US$238.28 | US$247.00 +3.7% | 10.7% | US$270.00 | US$183.00 | n/a | 15 |
| Feb ’25 | US$235.85 | US$234.73 -0.5% | 12.6% | US$267.00 | US$183.00 | n/a | 15 |
| Jan ’25 | US$203.94 | US$211.71 +3.8% | 6.7% | US$235.00 | US$176.00 | n/a | 14 |
| Dec ’24 | US$203.82 | US$208.92 +2.5% | 6.3% | US$223.00 | US$176.00 | n/a | 13 |
| Nov ’24 | US$188.18 | US$207.23 +10.1% | 8.4% | US$225.00 | US$162.00 | US$234.88 | 13 |
| Oct ’24 | US$180.35 | US$206.23 +14.3% | 8.1% | US$225.00 | US$162.00 | US$224.19 | 13 |
| Sep ’24 | US$175.12 | US$206.36 +17.8% | 7.9% | US$225.00 | US$162.00 | US$237.74 | 14 |
| Aug ’24 | US$188.51 | US$194.79 +3.3% | 8.9% | US$213.00 | US$149.00 | US$242.09 | 14 |
| Jul ’24 | US$192.71 | US$187.13 -2.9% | 8.1% | US$208.00 | US$149.00 | US$223.52 | 15 |
| Jun ’24 | US$172.09 | US$186.20 +8.2% | 7.6% | US$207.00 | US$149.00 | US$223.87 | 15 |
| May ’24 | US$166.25 | US$181.47 +9.2% | 7.1% | US$205.00 | US$149.00 | US$231.02 | 15 |
| Apr ’24 | US$159.57 | US$181.20 +13.6% | 6.9% | US$201.00 | US$149.00 | US$241.08 | 15 |
| Mar ’24 | US$156.30 | US$181.62 +16.2% | 7.2% | US$201.00 | US$149.00 | US$238.28 | 13 |
| Feb ’24 | US$163.88 | US$181.17 +10.6% | 7.9% | US$201.00 | US$149.00 | US$235.85 | 12 |
| Jan ’24 | US$164.75 | US$176.82 +7.3% | 7.0% | US$195.00 | US$148.00 | US$203.94 | 11 |
| Dec ’23 | US$171.39 | US$177.45 +3.5% | 6.2% | US$195.00 | US$155.00 | US$203.82 | 11 |
| Nov ’23 | US$157.85 | US$172.50 +9.3% | 6.4% | US$191.00 | US$155.00 | US$188.18 | 12 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$403.49
7D
0.4%
1Y
-15.5%
Enovis
US$2.7b
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
0I1B
US$48.46
7D
9.7%
1Y
-3.3%
Patterson Companies
US$1.9b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
0KGB
US$21.68
7D
7.0%
1Y
-14.5%